Source: GlobeNewswire

Press Release: Paratek : Paratek's NUZYRA (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market

-- Approximately One Third of Commercial Lives in U.S. had Access to NUZYRA by the End of the First Quarter 2019 ---- Significant Presence at ECCMID 2019 with Nine NUZYRA Presentations --

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Evan Loh's photo - CEO of Paratek


Evan Loh

CEO Approval Rating


Paratek is a biopharmaceutical company that develops antibiotic drugs to treat bacterial pneumonia in adults. Read more